Lexeo Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Lexeo Therapeutics (LXEO).

Price Target Range — 12 Quarters

Analyst Consensus — 11 Analysts

1S.Buy

10Buy

Consensus RatingBuy# Analysts11Avg. Consensus PT$19Upside to Avg. PT+606.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 23, 2026	Leerink Partners	Roanna Ruiz	Maintained	Outperform	$15
Jun 25, 2026	JP Morgan	Tessa Romero	PT Cut	Overweight	$12→$9
May 11, 2026	Chardan Capital	Geulah Livshits	Maintained	Buy	$17
Jan 13, 2026	Chardan Capital	Geulah Livshits	Maintained	Buy	$17
Jan 13, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$13→$10
Dec 18, 2025	Raymond James	Christopher Raymond	Initiate	Strong Buy	$25
Dec 11, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$17
Dec 1, 2025	Cantor Fitzgerald	Kristen Kluska	Initiate	Overweight	$19
Nov 20, 2025	Cantor Fitzgerald	Kristen Kluska	Initiate	Overweight	$19
Nov 5, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$17
Oct 21, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$15→$13
Oct 15, 2025	Guggenheim	Debjit Chattopadhyay	Initiate	Buy	$30
Oct 7, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$9→$15
Oct 7, 2025	Chardan Capital	Geulah Livshits	PT Raise	Buy	$15→$17
Oct 7, 2025	Leerink Partners	Mani Foroohar	PT Raise	Outperform	$9→$20
Aug 15, 2025	Leerink Partners	Mani Foroohar	PT Cut	Outperform	$15→$9
Aug 15, 2025	Chardan Capital	Geulah Livshits	PT Cut	Buy	$20→$15
Aug 15, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$15→$9
Jul 31, 2025	Oppenheimer	Leland Gershell	Initiate	Outperform	$20
May 30, 2025	JP Morgan	Tessa Romero	PT Cut	Overweight	$16→$10

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Lexeo Therapeutics, Lowers Price Target to $9

JP Morgan analyst Tessa Romero maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Overweight and lowers the price target from $12 to $9.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $17 Price Target

Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $17 price target.

Benzinga Newsdesk

Five Below To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Lexeo Therapeutics, Lowers Price Target to $10

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and lowers the price target from $13 to $10.

Benzinga Newsdesk

This Valvoline Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Avi Kapoor

PRO
Raymond James Initiates Coverage On Lexeo Therapeutics with Strong Buy Rating, Announces Price Target of $25

Raymond James analyst Christopher Raymond initiates coverage on Lexeo Therapeutics (NASDAQ:LXEO) with a Strong Buy rating and announces Price Target of $25.

Benzinga Newsdesk

Lexeo Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Lexeo Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Lexeo Therapeutics, Lowers Price Target to $9

PRO
Chardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $17 Price Target

Five Below To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday

PRO
HC Wainwright & Co. Maintains Buy on Lexeo Therapeutics, Lowers Price Target to $10

This Valvoline Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PRO
Raymond James Initiates Coverage On Lexeo Therapeutics with Strong Buy Rating, Announces Price Target of $25

People Also Watch

People Also Watch

Lexeo Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Lexeo Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Maintains Overweight on Lexeo Therapeutics, Lowers Price Target to $9

PROChardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $17 Price Target

Five Below To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday

PROHC Wainwright & Co. Maintains Buy on Lexeo Therapeutics, Lowers Price Target to $10

This Valvoline Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PRORaymond James Initiates Coverage On Lexeo Therapeutics with Strong Buy Rating, Announces Price Target of $25

People Also Watch

People Also Watch

PRO
JP Morgan Maintains Overweight on Lexeo Therapeutics, Lowers Price Target to $9

PRO
Chardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $17 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Lexeo Therapeutics, Lowers Price Target to $10

PRO
Raymond James Initiates Coverage On Lexeo Therapeutics with Strong Buy Rating, Announces Price Target of $25